InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 0 (0%)+
Announcement
Release
2 Jul 2026 8:23AM
Price at Release
$0.004
Full Release
download
Summary
AdAlta Limited, a developer of next-generation cellular immunotherapies for solid cancers, has entered a strategic collaboration with Oktopi AI to enhance research efficiency and strengthen product development decisions. This collaboration is part of AdAlta's broader strategy to integrate AI across its operations, aiming to improve the quality, efficiency, and success rate of its research and business development initiatives. The Oktopi Platform, a software-as-a-service solution, will aid AdAlta in planning and prioritizing research efforts, conducting due diligence, and making well-informed in-licensing decisions under its 'East to West' strategy. The collaboration leverages AI capabilities, such as AdAlta's in-house developed EMU AI agent built on Anthropic’s Claude, to systematically assess potential in-licensing assets. These AI tools are expected to add value by supporting sharper investment decisions and enhancing readiness for strategic partnerships, all while ensuring human experts remain in control of the decision-making process.
Key Points
  • AdAlta Limited collaborates with Oktopi AI to enhance research efficiency.
  • The collaboration aligns with AdAlta's strategy to integrate AI across its operations.
  • Oktopi's AI-enabled platform aids in planning, prioritizing research, and conducting due diligence.
  • AdAlta's in-house AI, EMU, built on Anthropic’s Claude, aids in assessing in-licensing assets.
  • AI tools are expected to support sharper investment decisions and strategic partnerships.
  • Human experts remain in control of AI-assisted decision-making processes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.